Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, leading and overseeing the company’s global oncology research and development activities.
In a pivotal Phase 3 randomized clinical trial, niraparib maintenance therapy has demonstrated remarkable efficacy for patients recently diagnosed with advanced ovarian cancer following initial platinum-based chemotherapy. This trial, involving 384 participants, unveiled the significant potential of niraparib in extending progression-free survival rates by a substantial 55% when compared to a placebo control group. Notably, the treatment’s effectiveness was observed across diverse patient subsets, regardless of their biomarker status or the presence of residual disease. These findings underscore the promising role of niraparib as a prospective standard-of-care option for an extensive spectrum of advanced ovarian cancer patients post-initial chemotherapy.